search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613
EISSN: 1998-3751
Vol. 40, No. 5, 2008, pp. 191-196
Bioline Code: ph08059
Full paper language: English
Document type: Symposium
Document available free of charge

Indian Journal of Pharmacology, Vol. 40, No. 5, 2008, pp. 191-196

 en Partial Nicotinic Acetylcholine (α4β2) Agonists as Promising New Medications for Smoking Cessation
Singh, J. & Budhiraja, Salil

Abstract

Objective: To review the pharmacology, clinical efficacy and safety of partial agonists of a4β 2 nicotinic acetylcholine receptor.
Data Sources: Primary literature and review articles were obtained via a PUBMED search (1988-August 2006) using the key terms smoking cessation, partial agonist alpha4beta2 nicotinic acetylcholine receptor, varenicline, cytisine and SSR591813. Additional studies and abstracts were identified from the bibliographies of reviewed literature.
Study Selection and Data Extraction: Studies and review articles related to varenicline, cytisine and the partial agonist alpha4beta2 nicotinic acetylcholine receptor were reviewed.
Data Synthesis: Smoking is widely recognized as a serious health problem. Smoking cessation has major health benefits. According to the US Public Health Services, all patients attempting to quit smoking should be encouraged to use one or more effective pharmacotherapy. Currently, along with nicotine replacement therapy, bupropion, nortriptyline and clonidine, are the mainstay of pharmacotherapy. More than ¾ of patients receiving treatment for smoking cessation return to smoking within the first year. Nicotine, through stimulating α4β 2 nAChR, releases dopamine in the reward pathway. Partial agonist of α4β 2 nAChR elicits moderate and sustained release of dopamine, which is countered during the cessation attempts; it simultaneously blocks the effects of nicotine by binding with α4β 2 receptors during smoking. Recently, varenicline, a partial agonist at α4β 2 nAChR, has been approved by the FDA (Food and Drug Administration) for smoking cessation.
Conclusion: Partial agonist α4β 2 nAChR appears to be a promising target in smoking cessation. Varenicline of this group is approved for treatment of smoking cessation by the FDA in May 2006.

Keywords
Cytisine, partial agonist α4β 2 nAChR, smoking cessation, SSR591813, varenicline

 
© Copyright 2008 Indian Journal of Pharmacology.
Alternative site location: http://www.ijp-online.com

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 09-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil